NasdaqGM - Nasdaq Real Time Price USD

HCW Biologics Inc. (HCWB)

1.4600

-0.1200

(-7.59%)

At close: April 25 at 4:00 PM EDT

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023. Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stat

GlobeNewswire 24 days ago

HCWB
-7.59%
Rebecca Byam Bought 122% More Shares In HCW Biologics

HCW Biologics Inc. ( NASDAQ:HCWB ) shareholders (or potential shareholders) will be happy to see that the Chief...

Simply Wall St. last month

HCWB
-7.59%
Several Insiders Invested In HCW Biologics Flagging Positive News

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 2 months ago

HCWB
-7.59%
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2023. A human data readout from the ongoing Phase 1 clinical trial to evaluate

GlobeNewswire 5 months ago

HCWB
-7.59%
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Showed HCW9218 clinical safety and tumor response endpointsfor 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and

GlobeNewswire 5 months ago

HCWB
-7.59%
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

HCW9218 is the lead product candidate of HCW Biologics Inc.MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing

GlobeNewswire 5 months ago

HCWB
-7.59%
Insider Buying: CFO Rebecca Byam Acquires 5,000 Shares of HCW Biologics Inc

On September 13, 2023, Rebecca Byam, the Chief Financial Officer (CFO) of HCW Biologics Inc (NASDAQ:HCWB), made a significant insider purchase of 5,000 shares of the company's stock.

GuruFocus.com 7 months ago

HCWB
-7.59%
Insider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics Inc

On September 12, 2023, Rebecca Byam, the Chief Financial Officer (CFO) of HCW Biologics Inc (NASDAQ:HCWB), made a significant insider purchase of 10,000 shares of the company's stock.

GuruFocus.com 7 months ago

HCWB
-7.59%
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 monthsMIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will participate

GlobeNewswire 7 months ago

HCWB
-7.59%
Insider Stock Buying Reaches US$845k On HCW Biologics

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 8 months ago

HCWB
-7.59%
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023. “During the period ended June 30, 2023, we have made significant progress in

GlobeNewswire 8 months ago

HCWB
-7.59%
The past year for HCW Biologics (NASDAQ:HCWB) investors has not been profitable

HCW Biologics Inc. ( NASDAQ:HCWB ) shareholders will doubtless be very grateful to see the share price up 56% in the...

Simply Wall St. 9 months ago

HCWB
-7.59%
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent Cells in Subjects with CancerMIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, wa

GlobeNewswire 10 months ago

HCWB
-7.59%
HCW Biologics First Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.057 loss in 1Q 2022)

HCW Biologics ( NASDAQ:HCWB ) First Quarter 2023 Results Key Financial Results Revenue: US$41.9k (down 99% from 1Q...

Simply Wall St. 11 months ago

HCWB
-7.59%
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2023. “We measure our progress over the past year by the achievement of significant

GlobeNewswire 11 months ago

HCWB
-7.59%
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, entered into a $26.25 million development line of credit agreemen

GlobeNewswire 11 months ago

HCWB
-7.59%

Performance Overview

Return	HCWB	S&P 500
YTD	+19.18%	+5.84%
1-Year	+3.18%	+22.03%
3-Year	--	+16.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

HCW Biologics Inc. (HCWB)

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Rebecca Byam Bought 122% More Shares In HCW Biologics

Several Insiders Invested In HCW Biologics Flagging Positive News

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

Insider Buying: CFO Rebecca Byam Acquires 5,000 Shares of HCW Biologics Inc

Insider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics Inc

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Insider Stock Buying Reaches US$845k On HCW Biologics

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

The past year for HCW Biologics (NASDAQ:HCWB) investors has not been profitable

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

HCW Biologics First Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.057 loss in 1Q 2022)

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Performance Overview